Clean Yield Group Trims Holdings in Pfizer Inc. (NYSE:PFE)

Clean Yield Group reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the third quarter, HoldingsChannel reports. The fund owned 14,169 shares of the biopharmaceutical company’s stock after selling 885 shares during the period. Clean Yield Group’s holdings in Pfizer were worth $410,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. LGT Group Foundation increased its position in Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares in the last quarter. ORG Partners LLC raised its position in shares of Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares during the last quarter. Kempner Capital Management Inc. bought a new position in Pfizer in the 1st quarter worth about $2,439,000. Leo Wealth LLC purchased a new stake in Pfizer during the 4th quarter valued at about $2,171,000. Finally, Power Corp of Canada grew its position in Pfizer by 28.1% during the 4th quarter. Power Corp of Canada now owns 174,201 shares of the biopharmaceutical company’s stock valued at $5,015,000 after purchasing an additional 38,243 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.06 on Tuesday, hitting $29.26. 3,741,634 shares of the company’s stock were exchanged, compared to its average volume of 37,273,449. The company has a 50-day simple moving average of $29.17 and a 200-day simple moving average of $28.32. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $33.92. The stock has a market capitalization of $165.80 billion, a PE ratio of -486.50, a PEG ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the business posted $0.67 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Finally, Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.